

**Bayer ARRIVE Trial Press Conference**

**14:00 to 15:00 CEST, Monday, 03 September, 2007**

**Vienna, Austria – European Society of Cardiology  
Industry Press Conference Room**

**AGENDA**

**ANNOUNCING THE ARRIVE STUDY**

<p>Panel Announcing ARRIVE: A Landmark Clinical Trial</p>	<p>Wes Cetnarowski, M.D., Senior Vice President, Bayer HealthCare Global CC Research &amp; Development</p>
<p>Advancing the Science of Aspirin in CVD Prevention Aspirin to Reduce Risk of Initial Vascular Events: The ARRIVE Study</p>	<p>J. Michael Gaziano, M.D., M.P.H., Chair of the ARRIVE Trial Executive Committee; Chief, Division of Aging at Brigham and Women's Hospital in Boston, Mass., USA; Director, Massachusetts Veterans Epidemiology, Research and Information Center and the Geriatric Research, Education and Clinical Center at VA Boston Healthcare System; Associate Professor at Harvard Medical School</p>
<p>Primary Prevention and the Way Forward: Advancing Identification of the At-Risk Patient</p>	<p>Harald Darius, M.D., Berlin, Germany, Chairman (2007 – 2009) of ALKK (working group of leading cardiology hospital physicians); Vivantes Klinikum Neukölln, Hospital of Cardiology, Internal Medicine and Conservative Intensive Medicine</p>
<p>Aspirin Underutilization: The Facts and the Socioeconomic Impact</p>	<p>Luis M. Ruilope, M.D., Associate Professor of Internal Medicine, Complutense University, Madrid, Spain; Head of Hypertension Unit, 12 de Octubre Hospital</p>
<p>Close and Q&amp;A</p>	<p>Panel</p>

